ImmunoCellular Therapeutics Stock Forecast, Price & News

+0.13 (+35.14 %)
(As of 04/9/2021 12:00 AM ET)
Today's Range
Now: $0.50
50-Day Range
MA: $0.69
52-Week Range
Now: $0.50
Volume4,698 shs
Average Volume24,458 shs
Market Capitalization$1.76 million
P/E RatioN/A
Dividend YieldN/A
ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company, develops immune-based therapies for the treatment of various cancers. Its products include ICT-107, a dendritic cell (DC) immunotherapy for the treatment of diagnosed glioblastoma multiforme (GBM); ICT-140, a DC-based immunotherapy targets tumor associated antigens on ovarian cancer; and ICT-121, a DC-based immunotherapy targeting CD133 markers and CSCs to treat recurrent GBM and other solid tumor cancers. The company is developing Steam-to-T-Cell immunotherapies for the treatment of cancer. It has license agreements with California Institute of Technology and The Johns Hopkins University. The company was formerly known as Optical Molecular Imaging, Inc. and changed its name to ImmunoCellular Therapeutics, Ltd. in November 2006. ImmunoCellular Therapeutics, Ltd. is based in Westlake Village, California.
ImmunoCellular Therapeutics logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolOTCMKTS:IMUC
Year FoundedN/A



Sales & Book Value

Annual SalesN/A



Market Cap$1.76 million
Next Earnings DateN/A
OptionableNot Optionable


Overall MarketRank

0.00 out of 5 stars

Medical Sector

1911th out of 2,010 stocks

Pharmaceutical Preparations Industry

748th out of 769 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
+0.13 (+35.14 %)
(As of 04/9/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive IMUC News and Ratings via Email

Sign-up to receive the latest news and ratings for IMUC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

ImmunoCellular Therapeutics (OTCMKTS:IMUC) Frequently Asked Questions

What stocks does MarketBeat like better than ImmunoCellular Therapeutics?

Wall Street analysts have given ImmunoCellular Therapeutics a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but ImmunoCellular Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting ImmunoCellular Therapeutics?

ImmunoCellular Therapeutics saw a decline in short interest in March. As of March 15th, there was short interest totaling 900 shares, a decline of 77.5% from the February 28th total of 4,000 shares. Based on an average daily volume of 14,500 shares, the short-interest ratio is presently 0.1 days.
View ImmunoCellular Therapeutics' Short Interest

How were ImmunoCellular Therapeutics' earnings last quarter?

ImmunoCellular Therapeutics, Ltd. (OTCMKTS:IMUC) released its earnings results on Monday, August, 13th. The company reported ($0.01) EPS for the quarter.
View ImmunoCellular Therapeutics' earnings history

Who are ImmunoCellular Therapeutics' key executives?

ImmunoCellular Therapeutics' management team includes the following people:
  • Mr. Gary S. Titus CPA, Independent Chairman & Corp. Sec. (Age 61, Pay $63k)
  • Mr. Sanford J. Hillsberg, Co-Founder (Age 72)
  • Dr. John S. Yu, Founder & Director (Age 57)

Who are some of ImmunoCellular Therapeutics' key competitors?

What is ImmunoCellular Therapeutics' stock symbol?

ImmunoCellular Therapeutics trades on the OTCMKTS under the ticker symbol "IMUC."

How do I buy shares of ImmunoCellular Therapeutics?

Shares of IMUC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ImmunoCellular Therapeutics' stock price today?

One share of IMUC stock can currently be purchased for approximately $0.50.

How much money does ImmunoCellular Therapeutics make?

ImmunoCellular Therapeutics has a market capitalization of $1.76 million.

How many employees does ImmunoCellular Therapeutics have?

ImmunoCellular Therapeutics employs 3 workers across the globe.

What is ImmunoCellular Therapeutics' official website?

The official website for ImmunoCellular Therapeutics is www.imuc.com.

Where are ImmunoCellular Therapeutics' headquarters?

ImmunoCellular Therapeutics is headquartered at 23622 CALABASAS ROAD SUITE 300, CALABASAS CA, 91302.

How can I contact ImmunoCellular Therapeutics?

ImmunoCellular Therapeutics' mailing address is 23622 CALABASAS ROAD SUITE 300, CALABASAS CA, 91302. The company can be reached via phone at 818-264-2300 or via email at [email protected]

This page was last updated on 4/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.